Johnson & Johnson has just been granted FDA approval on a revolutionary new anti-depressant. The new treatment, which is called Spravato (drug name esketamine) is a nasal spray that is meant to influence the NMDA receptor in the brain that has been linked to depression. FDA approval was granted after “statistically significant” effects were observed in […]
Source: uInterview
